🇺🇸 FDA
Patent

US 9675588

Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

granted A61KA61K31/4178A61K9/2013

Quick answer

US patent 9675588 (Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms) held by RedHill Biopharma Ltd. expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
RedHill Biopharma Ltd.
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/4178, A61K9/2013, A61K9/2054, A61K9/2077